Start of UK Confidential Haemophilia A Database: Analysis of 142 Patients by Solid Phase Fluorescent Chemical Cleavage of Mismatch

Summary

A national strategy for optimising genetic services in haemophilia A has been initiated in the UK. Solid phase fluorescent chemical cleavage of mismatch is used to screen the entire coding region of factor VIII in six segments: four amplified from the trace of mRNA in blood lymphocytes and two from genomic DNA for the 3.4 kb exon 14 and flanking intron sequences. These segments are analysed in two threefold multiplexes so that the genes of 18 patients can be screened in a single ABI 377 gel. The promoter and polyadenylation signal region are amplified and sequenced directly. We have analysed 142 unrelated patients and identified 141 factor VIII mutations and one Normandy type von Willebrand homozygote. The former mutations include 89 missense, 10 nonsense, 5 frameshift, one 24 bp deletion and one splice signal defect. These comprise 71 different changes, of which 39 have not been previously observed.

• References

• 1 Green PM, Montandon AJ, Ljung R, Bentley DR, Nilsson IM, Kling S, Giannelli F. Haemophilia B mutations in a complete Swedish population sample: a test of new strategy for the genetic counselling of diseases with high mutational heterogeneity. Brit J Haematol 1991; 78: 390-7.
• 2 Saad S, Rowley G, Taglivacca L, Green PM, Giannelli F. First report on UK database of haemophilia B mutations and pedigrees. UK Haemophilia Centres. Thromb Haemost 1994; 71: 563-70.
• 3 Gitschier J, Wood WI, Goralka TM, Wion KL, Chen EY, Eaton DH, Vehar GA, Capon DJ, Lawn RM. Characterization of the human factor VIII gene.. Nature 1984; 312: 326-30
• 4 Anson DS, Choo KH, Rees DJ, Giannelli F, Gould K, Huddleston JA, Brownlee GG. The gene structure of human anti-haemophilic factor IX.. EMBO J 1984; 3: 1053-60
• 5 Naylor JA, Green PM, Montandon AJ, Rizza CR, Giannelli F. Detection of three novel mutations in two haemophilia A patients by rapid screening of whole essential region of factor VIII gene.. Lancet 1991; 337: 635-9
• 6 Naylor JA, Green PM, Rizza CR, Giannelli F. Factor VIII gene explains all cases of haemophilia A.. Lancet 1992; 340: 1066-7
• 7 Lakich D, Kazazian Jr HH, Antonarakis SE, Gitschier J. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A.. Nat Genet 1993; 5: 236-41
• 8 Naylor J, Brinke A, Hassock S, Green PM, Giannelli F. Characteristic mRNA abnormality found in half the patients with severe haemophilia A is due to large DNA inversions.. Hum Mol Genet 1993; 2: 1773-8
• 9 Naylor JA, Buck D, Green P, Williamson H, Bentley D, Giannelli F. Investigation of the factor VIII intron 22 repeated region (int22h) and the associated inversion junctions.. Hum Mol Genet 1995; 4: 1217-24
• 10 Wood WI, Capon DJ, Simonsen CC, Eaton DL, Gitschier J, Keyt B, Seeburg PH, Smith DH, Hollingshead P, Wion KL. Expression of active human factor VIII from recombinant DNA clones.. Nature 1984; 312: 330-7
• 11 Rowley G, Saad S, Giannelli F, Green PM. Ultrarapid mutation detection by multiplex, solid-phase chemical cleavage.. Genomics 1995; 30: 574-82
• 12 Ramus SJ, Cotton RG. Single-tube chemical cleavage of mismatch: successive treatment with hydroxylamine and osmium tetroxide.. Biotechniques 1996; 21: 216-8
• 13 Schneppenheim R, Budde U, Krey S, Drewke E, Bergmann F, Lechler E, Oldenburg J, Schwaab R. Results of a screening for von Willebrand disease type 2N in patients with suspected haemophilia A or von Willebrand disease type 1.. Thromb Haemost 1996; 76: 598-602
• 14 Naylor JA.. Factor VIII gene mutations causing haemophilia A. PhD thesis; University of London: 1997
• 15 Watson HG, Ludlam CA. Immunological abnormalities in haemophiliacs.. Blood 1992; 6: 26-33
• 16 Naylor JA, Green PM, Rizza CR, Giannelli F. Analysis of factor VIII mRNA reveals defects in everyone of 28 haemophilia A patients.. Hum Mol Genet 1993; 2: 11-7
• 17 Tagliavacca L, Rowley G, Green PM, Hayden S, Woosey C, Colvin B. Analysis of the haemophila A mutation in sporadic patients registered at the Royal London Hospital and their families.. Haemophilia 1997; 3: 177-82
• 18 Hay CR, Ludlam CA, Colvin BT, Hill FG, Preston FE, Wasseem N, Bagnall R, Peake IR, Berntorp E, Mauser Bunschoten EP.. Factor VIII inhibitors in mild and moderate-severity haemophilia A UK Haemophilia Centre Directors Organisation.. Thromb Haemost 1998; 79: 762-6
• 19 Cooper DN, Youssoufian H. The CpG dinucleotide and human genetic disease.. Hum Genet 1988; 78: 151-5
• 20 Lenting PJ, Christophe OD, Maat H, Rees DJG, Mertens K. Ca2+ binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding.. J Biol Chem 1996; 271: 25332-7
• 21 Pittman DD, Kaufman RJ. Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII).. Proc Natl Acad Sci USA 1988; 85: 2429-33
• 22 Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine.. Blood 1990; 75: 1999-2004
• 23 McMullen BA, Fujikawa K, Davie EW, Hedner U, Ezban M. Locations of disulfide bonds and free cysteines in the heavy and light chains of recombinant human factor VIII (antihemophilic factor A).. Prot Science 1995; 4: 740-6
• 24 Haris II, Green PM, Bentley DR, Giannelli F. Mutation detection by fluorescent chemical cleavage: application to hemophilia B.. PCR Methods Appl 1994; 3: 268-71
• 25 Verpy E, Biasotto M, Meo T, Tosi M. Efficient detection of point mutations in color-coded strands of target DNA.. Proc Natl Acad Sci USA 1994; 91: 1873-7
• 26 Freson K, Peerlinck K, Aguirre T, Arnout J, Vermylen J, Cassiman JJ, Matthijs G. Fluorescent chemical cleavage of mismatches for efficient screening of the factor VIII gene.. Hum Mut 1998; 11: 470-9
• 27 Forrest SM, Dahl HH, Howells DN, Dianzani I, Cotton RGH. Mutation detection in phenylketonuria using the chemical cleavage of mismatch method: importance of using probes from both normal and patient samples.. Am J Hum Genet 1991; 49: 175-83
• 28 Green PM, Waseem NH, Bagnall RD, Giannelli F. Mutation analysis and genetic services: the construction and use of national confidential databases of mutation and pedigrees.. Genetic Testing 1998; 1: 181-8
• 29 Kemball-Cook G, Tuddenham EGD, Wacey AI. The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4.. Nucleic Acids Res 1998; 26: 216-9
• 30 Healey JF, Lubin IM, Lollar P. The cDNA and derived amino acid sequence of porcine factor VIII.. Blood 1996; 88: 4209-14
• 31 Cameron C, Notley C, Hoyle S, McGlynn L, Hough C, Kamisue S, Giles A, Lillicrap D. The canine factor VIII cDNA and 5’ flanking sequence.. Thromb Haemost 1998; 79: 317-22
• 32 Elder B, Lakich D, Gitschier J. Sequence of the murine factor VIII cDNA.. Genomics 1993; 16: 374-9
• 33 Jenny RJ, Pittman DD, Toole JJ, Kriz RW, Aldape RA, Hewick RM, Kaufman RJ, Mann KG. Complete cDNA and derived amino acid sequence of human factor V.. Proc Natl Acad Sci USA 1987; 84: 4846-50
• 34 Koschinsky ML, Funk WD, van Oost BA, MacGillivray RT. Complete cDNA sequence of human preceruloplasmin.. Proc Natl Acad Sci USA 1986; 83: 5086-90